Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00227
|
|||||
| Drug Name |
Rivaroxaban
|
|||||
| Synonyms |
XARELTO (TN)
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Prophylaxis of deep vein thrombosis [ICD11:BD71] | Approved | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C19H18ClN3O5S
|
|||||
| Canonical SMILES |
C1COCC(=O)N1C2=CC=C(C=C2)N3CC(OC3=O)CNC(=O)C4=CC=C(S4)Cl
|
|||||
| InChI |
InChI=1S/C19H18ClN3O5S/c20-16-6-5-15(29-16)18(25)21-9-14-10-23(19(26)28-14)13-3-1-12(2-4-13)22-7-8-27-11-17(22)24/h1-6,14H,7-11H2,(H,21,25)/t14-/m0/s1
|
|||||
| InChIKey |
KGFYHTZWPPHNLQ-AWEZNQCLSA-N
|
|||||
| CAS Number |
CAS 366789-02-8
|
|||||
| Pharmaceutical Properties | Molecular Weight | 435.9 | Topological Polar Surface Area | 116 | ||
| Heavy Atom Count | 29 | Rotatable Bond Count | 5 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 6 | |||
| XLogP |
2.5
|
|||||
| PubChem CID | ||||||
| PubChem SID |
103469795
,109693118
,126659499
,126666963
,134342998
,134358083
,135213418
,135684125
,136375511
,136920411
,137128738
,139479843
,14856850
,152258851
,152344334
,15279667
,160645892
,160647701
,160969514
,162172236
,164045359
,164194090
,164824489
,165245531
,170498903
,171578894
,172091286
,174477515
,175266472
,175427064
,175610897
,177748765
,178103004
,180189087
,185985285
,198991713
,22395270
,24164597
,45622373
,46513422
,51091428
,52936629
,56373953
,57373622
,71825413
,87225360
,87557471
,91615930
,93580340
,99444948
|
|||||
| ChEBI ID |
ChEBI:68579
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [3] | ||
| References | ||||||
| 1 | Rivaroxaban was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Absence of both MDR1 (ABCB1) and breast cancer resistance protein (ABCG2) transporters significantly alters rivaroxaban disposition and central nervous system entry. Basic Clin Pharmacol Toxicol. 2013 Mar;112(3):164-70. | |||||
| 3 | Downregulation of ABCB1 gene in patients with total hip or knee arthroplasty influences pharmacokinetics of rivaroxaban: a population pharmacokinetic-pharmacodynamic study. Eur J Clin Pharmacol. 2019 Feb 6. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.